The DOI matches its Crossref record; 243 of the 244 references it cites were found in a registry or an index.
Effects of cannabidiol interactions with Wnt/β-catenin pathway and PPARγ on oxidative stress and neuroinflammation in Alzheimer's disease
Abstract
Alzheimer's disease (AD) is a neurodegenerative disease, in which the primary etiology remains unknown. AD presents amyloid beta (Aβ) protein aggregation and neurofibrillary plaque deposits. AD shows oxidative stress and chronic inflammation. In AD, canonical Wingless-Int (Wnt)/β-catenin pathway is downregulated, whereas peroxisome proliferator-activated receptor γ (PPARγ) is increased. Downregulation of Wnt/β-catenin, through activation of glycogen synthase kinase-3β (GSK-3β) by Aβ, and inactivation of phosphatidylinositol 3-kinase/Akt signaling involve oxidative stress in AD. Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid from Cannabis sativa plant. In PC12 cells, Aβ-induced tau protein hyperphosphorylation is inhibited by CBD. This inhibition is associated with a downregulation of p-GSK-3β, an inhibitor of Wnt pathway. CBD may also increase Wnt/β-catenin by stimulation of PPARγ, inhibition of Aβ and ubiquitination of amyloid precursor protein. CBD attenuates oxidative stress and diminishes mitochondrial dysfunction and reactive oxygen species generation. CBD suppresses, through activation of PPARγ, pro-inflammatory signaling and may be a potential new candidate for AD therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In PC12 neuronal cells, CBD has shown protection against oxidative stress, Aβ-induced neurotoxicity, inhibition of tau hyperphosphorylation, prevention of proinflammatory gene transcription, and inhibition of Aβ-induced tau hyperphosphorylation [188,189].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [188]
In the citing paper
“In PC12 neuronal cells, CBD has shown protection against oxidative stress, Aβ-induced neurotoxicity, inhibition of tau hyperphosphorylation, prevention of proinflammatory gene transcription, and inhibition of Aβ-induced tau hyperphosphorylation [188,189].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [188]
In the citing paper
“In PC12 neuronal cells, CBD has shown protection against oxidative stress, Aβ-induced neurotoxicity, inhibition of tau hyperphosphorylation, prevention of proinflammatory gene transcription, and inhibition of Aβ-induced tau hyperphosphorylation [188,189].”
From The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment (2022) · cites this paper as [188]
Citations
Cites
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
Wnt/β-catenin signaling and disease
Clevers, H., & Nusse, R. (2012) · Cell · doi:10.1016/j.cell.2012.05.012 · Cited by 5,554
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
The Global Deterioration Scale for assessment of primary degenerative dementia
Reisberg, ., Ferris, S. H., de Leon, M. J., & Crook, T. H. (1982) · American Journal of Psychiatry · doi:10.1176/ajp.139.9.1136 · Cited by 5,122
Identification of c- MYC as a Target of the APC Pathway
He, T.-C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · Science · doi:10.1126/science.281.5382.1509 · Cited by 4,566
Mechanisms underlying inflammation in neurodegeneration
Glass, C. K., Saijo, K., Winner, B., Marchetto, M. C., & Gage, F. H. (2010) · Cell · doi:10.1016/j.cell.2010.02.016 · Cited by 3,580
Signaling to NF-κB by Toll-like receptors
Kawai, T., & Akira, S. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.09.002 · Cited by 2,468
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
Research works printed but not linked: 2
- Martín-Moreno AM, Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease. Mol Pharmacol, 2011, 79: 964-973. · DOI
- Sonego AB, Sepulveda-Diaz JE, Michel PP, Del-Bel EA, Guimarães FS, Raisman-Vozari R. Cannabidiol reduces LPS-induced activation and oxidative stress in primary microglial culture via PPARgamma receptor. Soc Neurosci Annu Meet, 2015, 58:
Cited by
Sorted by citations
Antioxidative and Anti-Inflammatory Properties of Cannabidiol
Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019) · Antioxidants · doi:10.3390/antiox9010021 · Cited by 889
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 499
Vallée, A., & Lecarpentier, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00745 · Cited by 380
Self-citationUse of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials
Silvestro, S., Mammana, S., Cavalli, E., Bramanti, P., & Mazzon, E. (2019) · Molecules · doi:10.3390/molecules24081459 · Cited by 249
Metabolic Dysregulation Contributes to the Progression of Alzheimer’s Disease
Yan, X., Hu, Y., Wang, B., Wang, S., & Zhang, X. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.530219 · Cited by 230
TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts
Vallée, A., & Lecarpentier, Y. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0362-3 · Cited by 205
Self-citationNouri, Z., Fakhri, S., El‐Senduny, F. F., Sanadgol, N., Abdel‐Ghani, G. E., Farzaei, M. H., & Chen, J. (2019) · Biomolecules · doi:10.3390/biom9110690 · Cited by 173
The Polypharmacological Effects of Cannabidiol
Castillo-Arellano, J. I., Canseco-Alba, A., Cutler, S. J., & León, F. (2023) · Molecules · doi:10.3390/molecules28073271 · Cited by 172
Neuroinflammation in Schizophrenia: The Key Role of the WNT/β-Catenin Pathway
Vallée, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052810 · Cited by 156
Self-citationCassano, T., Villani, R., Pace, L., Carbone, A., Bukke, V. N., Orkisz, S., Avolio, C., & Serviddio, G. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00124 · Cited by 156
Neurogenesis After Stroke: A Therapeutic Perspective
Rahman, A. A., Amruta, N., Pinteaux, E., & Bix, G. J. (2020) · Translational Stroke Research · doi:10.1007/s12975-020-00841-w · Cited by 147
A systematic review of minor phytocannabinoids with promising neuroprotective potential
Stone, N. L., Murphy, A. J., England, T. J., & O’Sullivan, S. E. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15185 · Cited by 121
Single-cell RNA sequencing reveals B cell–related molecular biomarkers for Alzheimer’s disease
Xiong, L.-L., Xue, L.-L., Du, R.-L., Niu, R.-Z., Chen, L., Chen, J., Hu, Q., Tan, Y.-X., Shang, H.-F., Liu, J., et al. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00714-8 · Cited by 114
PPAR Gamma: From Definition to Molecular Targets and Therapy of Lung Diseases
de Carvalho, M. V., Gonçalves-de-Albuquerque, C. F., & Silva, A. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020805 · Cited by 115
Yang, Y., Wang, L., Zhang, C., Guo, Y., Li, J., Wu, C., Jiao, J., & Zheng, H. Y. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14041 · Cited by 99
Silote, G. P., Sartim, A. G., Sales, A. J., Eskelund, A., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2019) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2019.04.006 · Cited by 98
Premature cell senescence in human skin: Dual face in chronic acquired pigmentary disorders
Bellei, B., & Picardo, M. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100981 · Cited by 93
Warburg effect hypothesis in autism Spectrum disorders
Vallée, A., & Vallée, J.-N. (2018) · Molecular Brain · doi:10.1186/s13041-017-0343-6 · Cited by 92
Self-citationMolecular Targets of Cannabidiol in Experimental Models of Neurological Disease
Silvestro, S., Schepici, G., Bramanti, P., & Mazzon, E. (2020) · Molecules · doi:10.3390/molecules25215186 · Cited by 93
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2017) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0550-9 · Cited by 88
Self-citationGu, Z., Singh, S., Niyogi, R. G., Lamont, G. J., Wang, H., Lamont, R. J., & Scott, D. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02288 · Cited by 88
Naringenin: A prospective therapeutic agent for Alzheimer's and Parkinson's disease
Goyal, A., Verma, A., Dubey, N., Raghav, J., & Agrawal, A. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14415 · Cited by 77
Flack, N., Colwell, M., Drown, C., & Faulk, C. D. (2021) · Clinical Epigenetics · doi:10.1186/s13148-020-00993-4 · Cited by 72
Cannabidiol Reverses Deficits in Hippocampal LTP in a Model of Alzheimer’s Disease
Hughes, B., & Herron, C. E. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2513-z · Cited by 72
Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Shri, S. R., Manandhar, S., Nayak, Y., & Pai, K. S. R. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.071 · Cited by 71
Ożarowski, M., Karpiński, T. M. M., Zielińska, A., Souto, E. B., & Wielgus, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094294 · Cited by 71
Gęgotek, A., Atalay, S., Domingues, P. M., & Skrzydlewska, E. (2019) · Cells · doi:10.3390/cells8090995 · Cited by 63
Identification of molecular correlations of RBM8A with autophagy in Alzheimer's disease
Zou, D., Li, R., Huang, X., Chen, G., Liu, Y., Meng, Y., Wang, Y., Wu, Y., & Mao, Y. (2019) · Aging · doi:10.18632/aging.102571 · Cited by 62
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0219-5 · Cited by 62
Self-citationGlycogen Synthase Kinase 3 (GSK3): Its Role and Inhibitors
Wadhwa, P. K., Jain, P., & Jadhav, H. R. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200516153136 · Cited by 61
Jin, D., Henry, P., Shan, J. J., & Chen, J. (2021) · Frontiers in Plant Science · doi:10.3389/fpls.2021.699530 · Cited by 63
Traditional Herbal Medicines Against CNS Disorders from Bangladesh
Uddin, M. J., & Zidorn, C. (2020) · Natural Products and Bioprospecting · doi:10.1007/s13659-020-00269-7 · Cited by 66
Salem, M. A., Budzyńska, B., Kowalczyk, J., Sayed, N. S. E., & Mansour, S. M. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115697 · Cited by 61
Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington’s disease
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0075 · Cited by 59
Self-citationVallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041212 · Cited by 59
Self-citationWang, Y., Zhu, T., Wang, M., Zhang, F., Zhang, G., Zhao, J., Zhang, Y., Wu, E., & Li, X. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00291 · Cited by 58
Maurya, S. K., Bhattacharya, N., Mishra, S., Bhattacharya, A., Banerjee, P., Senapati, S., & Mishra, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.654489 · Cited by 59
Jha, N. K., Chen, W., Kumar, S., Dubey, R., Tsai, L.-W., Kar, R., Jha, S. K., Gupta, P. K., Sharma, A., Gundamaraju, R., et al. (2022) · Open Biology · doi:10.1098/rsob.210289 · Cited by 62
Cannabidiol goes nuclear: The role of PPARγ
Khosropoor, S., Alavi, M. S., Etemad, L., & Roohbakhsh, A. (2023) · Phytomedicine · doi:10.1016/j.phymed.2023.154771 · Cited by 58
Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease
Xiong, Y., & Lim, C. (2021) · Brain Sciences · doi:10.3390/brainsci11091211 · Cited by 60
Natural products for male androgenetic alopecia
Gupta, A. K., Talukder, M., & Bamimore, M. A. (2022) · Dermatologic Therapy · doi:10.1111/dth.15323 · Cited by 55
Is There a Future for PPARs in the Treatment of Neuropsychiatric Disorders?
Tufano, M., & Pinna, G. (2020) · Molecules · doi:10.3390/molecules25051062 · Cited by 57
Bonnet, C., Brahmbhatt, A., Deng, S. X., & Zheng, J. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00063b · Cited by 56
Sun, L., Qi, J., & Gao, R. (2018) · Brain Research · doi:10.1016/j.brainres.2018.04.040 · Cited by 53
Jîtcă, G., Ősz, B. E., Vari, C.-E., Rusz, C.-M., Tero-Vescan, A., & Puşcaş, A. (2023) · Antioxidants · doi:10.3390/antiox12020485 · Cited by 58
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2018) · NeuroMolecular Medicine · doi:10.1007/s12017-018-8486-x · Cited by 54
Self-citationTherapeutic properties of multi-cannabinoid treatment strategies for Alzheimer’s disease
Coles, M., Steiner-Lim, G. Z., & Karl, T. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.962922 · Cited by 57
Riluzole: a therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathway
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2020) · Aging · doi:10.18632/aging.102830 · Cited by 50
Self-citationCannabidiol Inhibits Tau Aggregation In Vitro
Alali, S., Riazi, G. H., Ashrafi-Kooshk, M. R., Meknatkhah, S., Ahmadian, S., Ardakani, M. H., & Hosseinkhani, B. (2021) · Cells · doi:10.3390/cells10123521 · Cited by 48
Blagodatski, A. S., Klimenko, A., Jia, L., & Katanaev, V. L. (2020) · Cells · doi:10.3390/cells9030589 · Cited by 46
Pérez-Olives, C., Rivas‐Santisteban, R., Lillo, J., Navarro, G., & Franco, R. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_6 · Cited by 46
Vallée, A., Vallée, J.-N., & Lecarpentier, Y. (2021) · Aging · doi:10.18632/aging.202951 · Cited by 47
Self-citationTHC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Pintori, N., Caria, F., Luca, M. A. D., & Miliano, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065251 · Cited by 50
Wang, S., Du, P., Cao, Y., Ma, J., Yang, X. F., Yu, Z., & Yang, Y. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01163-6 · Cited by 45
Reddy, V. P., Grogan, D. P., Ahluwalia, M., Salles, É. L., Ahluwalia, P. K., Khodadadi, H., Alverson, K., Nguyen, A., Raju, S. P., Gaur, P., et al. (2020) · The EPMA Journal · doi:10.1007/s13167-020-00203-4 · Cited by 45
To, J. C., Chiu, A. P., Tschida, B. R., Lo, L. H., Chiu, C. H., Li, X.-X., Kuka, T. P., Linden, M. A., Amin, K., Chan, W.-C., et al. (2020) · JHEP Reports · doi:10.1016/j.jhepr.2020.100223 · Cited by 42
Alzheimer’s Disease and Protein Kinases
Engin, A. B., & Engin, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49844-3_11 · Cited by 43
Reece, A. S., & Hulse, G. K. (2022) · BMC Pediatrics · doi:10.1186/s12887-021-02996-3 · Cited by 41
Scarante, F. F., Ribeiro, M. A., Almeida-Santos, A. F., Guimarães, F. S., & Campos, A. C. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.618065 · Cited by 44
Zhou, J., Wu, N., & Lin, L.-Y. (2020) · Medical Science Monitor · doi:10.12659/msm.920445 · Cited by 39
Cannabidiol and the Canonical WNT/β-Catenin Pathway in Glaucoma
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073798 · Cited by 40
Self-citationAziz, A.-I., Nguyen, L. C., Oumeslakht, L., Bensussan, A., & Mkaddem, S. B. (2022) · Cannabis and Cannabinoid Research · doi:10.1089/can.2022.0133 · Cited by 41
A Review on Studies of Marijuana for Alzheimer’s Disease – Focusing on CBD, THC
Kim, S. H., Yang, J. W., Kim, K. H., Kim, J. U., & Yook, T. H. (2019) · Journal of pharmacopuncture · doi:10.3831/kpi.2019.22.030 · Cited by 42
Reprogramming energetic metabolism in Alzheimer's disease
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.10.033 · Cited by 38
Self-citationLiu, X., Wang, K., Wei, X., Xie, T., Lv, B., Zhou, Q., & Wang, X. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03227-y · Cited by 37
Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Franco, G. D. R. R., Smid, S. D., & Viegas, C. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200720172624 · Cited by 37
Cannabinoids for skin diseases and hair regrowth
Gupta, A., & Talukder, M. (2021) · Journal of Cosmetic Dermatology · doi:10.1111/jocd.14352 · Cited by 35
Viana, M. D. B., de Aquino, P. E. A., Estadella, D., Ribeiro, D. A., & Viana, G. S. D. B. (2022) · Medical Cannabis and Cannabinoids · doi:10.1159/000527335 · Cited by 37
Update on Cannabidiol Clinical Toxicity and Adverse Effects: A Systematic Review
Madeo, G., Kapoor, A., Giorgetti, R., Busardò, F. P., & Carlier, J. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230322143401 · Cited by 43
Matrisciano, F., & Pinna, G. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100222 · Cited by 35
Investigation of Cannabis sativa Phytochemicals as Anti-Alzheimer’s Agents: An In Silico Study
Patil, N., Chandel, V., Rana, A., Jain, M., & Kaushik, P. (2023) · Plants · doi:10.3390/plants12030510 · Cited by 36
Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies
Veiga, M., Azevedo‐Silva, J., & Fernandes, J. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020155 · Cited by 36
Neuroprotective potential of cannabidiol: Molecular mechanisms and clinical implications
Tambe, S. M., Mali, S. N., Amin, P. D., & de Oliveira, M. S. (2023) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2023.03.004 · Cited by 34
Furqan, T., Batool, S., Habib, R., Shah, M., Kalász, H., Darvas, F., Kuča, K., Nepovimová, E., Batool, S., & Nurulain, S. M. (2020) · Biomolecules · doi:10.3390/biom10050758 · Cited by 35
Giacobbe, J., Marrocu, A., Benedetto, M. G. D., Pariante, C. M., & Borsini, A. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.12.024 · Cited by 36
Therapeutic Potential of Wnt-3a in Neurological Recovery after Spinal Cord Injury
Gao, K., Zhang, T., Wang, F., & Lv, C. (2019) · European Neurology · doi:10.1159/000502004 · Cited by 32
Role of cannabinoids in alcohol-induced neuroinflammation
García-Baos, A., Alegre-Zurano, L., Cantacorps, L., Martín‐Sánchez, A., & Valverde, O. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110054 · Cited by 34
Chang, R. C.-A., Thangavelu, C. S., Joloya, E. M., Kuo, Y., Li, Z., & Blumberg, B. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114910 · Cited by 34
Vallée, A., Levy, B. I., & Blacher, J. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0860-4 · Cited by 32
Self-citationCannabidiol in sport: Ergogenic or else?
Gamelin, F.-X., Cuvelier, G., Mendes, A., Aucouturier, J., Berthoin, S., Marzo, V. D., & Heyman, E. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104764 · Cited by 38
Identification of potential biomarkers for pathogenesis of Alzheimer’s disease
Wang, H., Han, X., & Gao, S. (2021) · Hereditas · doi:10.1186/s41065-021-00187-9 · Cited by 34
Costa, A. C., Joaquim, H. P. G., Pedrazzi, J. F. C., Pain, A. D. O., Duque, G., & Aprahamian, I. (2022) · Brain Sciences · doi:10.3390/brainsci12121596 · Cited by 38
Adverse Impact of Cannabis on Human Health
Chandy, M., Nishiga, M., Wei, T.-T., Hamburg, N. M., Nadeau, K. C., & Wu, J. C. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-052422-020627 · Cited by 33
Cannabidiol and neurodegeneration: From molecular mechanisms to clinical benefits
Jha, S. K., Nelson, V. K., Suryadevara, P. R., Panda, S. P., Pullaiah, C. P., Nuli, M. V., Kamal, M., Imran, M., Ausali, S., Abomughaid, M. M., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102386 · Cited by 32
PPARγ agonists: Potential treatments for exudative age-related macular degeneration
Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.09.008 · Cited by 29
Self-citationSubacute cannabidiol alters genome‐wide DNA methylation in adult mouse hippocampus
Flack, N., Colwell, M., Drown, C., & Faulk, C. D. (2020) · Environmental and Molecular Mutagenesis · doi:10.1002/em.22396 · Cited by 31
Vigli, D., Cosentino, L., Pellas, M., & Filippis, B. D. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.09.041 · Cited by 32
The Multifaceted Role of Neuroprotective Plants in Alzheimer’s Disease Treatment
Zieneldien, T., Kim, J., & Cao, C. (2022) · Geriatrics · doi:10.3390/geriatrics7020024 · Cited by 29
“bition of tau hyperphosphorylation, prevention of proinflammatory gene transcription, and inhibition of Aβ-induced tau hyperphosphorylation [188,189].”
BackgroundReece, A. S., & Hulse, G. K. (2022) · Current Zoology · doi:10.1093/eep/dvab015 · Cited by 30
Effect of long-term cannabidiol on learning and anxiety in a female Alzheimer’s disease mouse model
Chesworth, R., Cheng, D., Staub, C., & Karl, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.931384 · Cited by 33
PPAR Gamma and Viral Infections of the Brain
Layrolle, P., Payoux, P., & Chavanas, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168876 · Cited by 28
Nagu, P., Sharma, V., Behl, T., Pathan, A. K., & Mehta, V. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01940-5 · Cited by 28
Butterfield, D. A., Favia, M., Spera, I., Campanella, A., Lanza, M., & Castegna, A. (2022) · Molecules · doi:10.3390/molecules27030951 · Cited by 29
Costa, A., Russo, F., Senn, L., Ibatici, D., Cannazza, G., & Biagini, G. (2022) · Pharmaceuticals · doi:10.3390/ph15050495 · Cited by 29
Wu, J., Chen, N., Liu, Y., Godlewski, G., Kaplan, H. J., Shrader, S. H., Song, Z.-H., & Shao, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251677 · Cited by 27
DeMarino, C., Cowen, M., Khatkar, P., Cotto, B., Branscome, H., Kim, Y., Sharif, S. A., Agbottah, E. T., Zhou, W., Costiniuk, C. T., et al. (2022) · Cells · doi:10.3390/cells11040723 · Cited by 27
Is cannabidiol a drug acting on unconventional targets to control drug‐resistant epilepsy?
Rocha, L., Frías‐Soria, C. L., Ortíz, J. G., Auzmendi, J., & Lazarowski, A. (2020) · Epilepsia Open · doi:10.1002/epi4.12376 · Cited by 25
The role of Wnt/mTOR signaling in spinal cord injury
Peng, C. M., Liao, H.-Y., & Zhang, H. (2022) · Journal of Clinical Orthopaedics and Trauma · doi:10.1016/j.jcot.2022.101760 · Cited by 24
Reece, A. S., & Hulse, G. K. (2022) · Archives of Public Health · doi:10.1186/s13690-022-00812-7 · Cited by 24
Characterization of the biochemical and behavioral effects of cannabidiol: implications for migraine
Greco, R., Francavilla, M., Demartini, C., Zanaboni, A. M., Sodergren, M. H., Facchetti, S., Pacchetti, B., Palmisani, M., Franco, V., & Tassorelli, C. (2023) · The Journal of Headache and Pain · doi:10.1186/s10194-023-01589-y · Cited by 26
Metadata
- Authors
- Vallée, A., Lecarpentier, Y., Guillevin, R., & Vallée, J.-N.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Venue
- Acta Biochimica et Biophysica Sinica
- Published
- 2017-10-01
- Volume
- 49
- Issue
- 10
- Pages
- 853-866
- ISSN
- 1672-9145 (ISSN-L)
- OpenAlex
- W2738129635
- Cited by
- 226
- References
- 244
- Citations by year
- 2026: 20 · 2025: 17 · 2024: 26 · 2023: 29 · 2022: 37 · 2021: 37 · 2020: 31 · 2019: 16 · 2018: 9 · 2017: 4
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Acta Biochimica et Biophysica Sinica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Complementary and alternative medicine › Medicinal Plants and Neuroprotection
- Keywords
- cannabidiol, Alzheimer's disease, Wnt/β-catenin signaling, PPARγ, oxidative stress, neuroinflammation, amyloid-beta, glycogen synthase kinase-3β, tau hyperphosphorylation, phosphatidylinositol 3-kinase/Akt signaling, mitochondrial dysfunction, reactive oxygen species, neuroprotection
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Alzheimer Disease, Animals, Cannabidiol, Inflammation, Models, Biological, Phosphorylation, Amyloid beta-Peptides, PC12 Cells, Neurofibrillary Tangles, tau Proteins, Oxidative Stress, PPAR gamma, Rats, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
